OMERS ADMINISTRATION Corp bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 23,300 shares of the biopharmaceutical company’s stock, valued at approximately $1,649,000.
A number of other hedge funds also recently modified their holdings of GILD. Parnassus Investments CA boosted its position in shares of Gilead Sciences by 37.4% during the first quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock worth $1,110,228,000 after buying an additional 4,556,901 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Gilead Sciences by 9.8% during the first quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock worth $2,076,368,000 after buying an additional 2,727,063 shares during the period. Pioneer Investment Management Inc. boosted its position in shares of Gilead Sciences by 84.0% during the second quarter. Pioneer Investment Management Inc. now owns 3,493,148 shares of the biopharmaceutical company’s stock worth $247,245,000 after buying an additional 1,595,085 shares during the period. Neuberger Berman Group LLC boosted its position in shares of Gilead Sciences by 90.9% during the second quarter. Neuberger Berman Group LLC now owns 2,583,196 shares of the biopharmaceutical company’s stock worth $182,839,000 after buying an additional 1,229,916 shares during the period. Finally, Harbour Capital Advisors LLC boosted its position in shares of Gilead Sciences by 6,595.9% during the second quarter. Harbour Capital Advisors LLC now owns 1,221,804 shares of the biopharmaceutical company’s stock worth $17,262,000 after buying an additional 1,203,557 shares during the period. Institutional investors own 74.28% of the company’s stock.
In related news, EVP Gregg H. Alton sold 25,000 shares of the firm’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $83.05, for a total transaction of $2,076,250.00. Following the sale, the executive vice president now directly owns 101,488 shares in the company, valued at $8,428,578.40. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $82.56, for a total transaction of $6,054,372.48. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 358,486 shares of company stock worth $29,637,678. 1.30% of the stock is currently owned by company insiders.
GILD has been the subject of several analyst reports. Berenberg Bank set a $96.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research report on Thursday, October 19th. Morgan Stanley reiterated an “equal weight” rating on shares of Gilead Sciences in a research report on Tuesday, July 11th. Royal Bank Of Canada initiated coverage on Gilead Sciences in a research report on Thursday, September 14th. They set an “outperform” rating and a $94.00 price objective for the company. Robert W. Baird reiterated an “outperform” rating and set a $87.00 price objective on shares of Gilead Sciences in a research report on Tuesday, August 29th. Finally, J P Morgan Chase & Co set a $85.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $85.68.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same period last year, the business posted $2.75 earnings per share. The firm’s quarterly revenue was down 13.2% on a year-over-year basis.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a dividend of $0.52 per share. The ex-dividend date is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.82%. Gilead Sciences’s payout ratio is 23.69%.
COPYRIGHT VIOLATION NOTICE: “OMERS ADMINISTRATION Corp Buys New Position in Gilead Sciences, Inc. (GILD)” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.com-unik.info/2017/11/03/omers-administration-corp-buys-new-position-in-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
What are top analysts saying about Gilead Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences Inc. and related companies.